Vcanbio Cell & Gene Engineering Corp., Ltd

Shanghai Stock Exchange 600645.SS

Vcanbio Cell & Gene Engineering Corp., Ltd Return on Equity (ROE) for the year ending December 31, 2023: 2.89%

Vcanbio Cell & Gene Engineering Corp., Ltd Return on Equity (ROE) is 2.89% for the year ending December 31, 2023, a -9.06% change year over year. Return on equity measures profit against shareholder equity; higher ROE indicates superior profitability and value creation.
  • Vcanbio Cell & Gene Engineering Corp., Ltd Return on Equity (ROE) for the year ending December 31, 2022 was 3.18%, a -29.14% change year over year.
  • Vcanbio Cell & Gene Engineering Corp., Ltd Return on Equity (ROE) for the year ending December 31, 2021 was 4.48%, a 220.00% change year over year.
  • Vcanbio Cell & Gene Engineering Corp., Ltd Return on Equity (ROE) for the year ending December 31, 2020 was -3.74%, a -352.20% change year over year.
  • Vcanbio Cell & Gene Engineering Corp., Ltd Return on Equity (ROE) for the year ending December 31, 2019 was 1.48%, a -30.66% change year over year.
Key data
Date Return on Equity (ROE) Return on Capital Employed (ROCE) Interest Coverage Ratio Debt to Equity Ratio
Market news
Loading...
Shanghai Stock Exchange: 600645.SS

Vcanbio Cell & Gene Engineering Corp., Ltd

CEO Mr. Hongqi Wang
IPO Date May 4, 1993
Location China
Headquarters Huayuan Industrial Park
Employees 2,209
Sector Health Care
Industries
Description

Vcanbio Cell & Gene Engineering Corp., Ltd, together with its subsidiaries, primarily engages in the preparation and storage of cell tests in the People's Republic of China. The company provides cell test preparation and storage services for umbilical cord blood hematopoietic stem cells, umbilical cord mesenchymal stem cells, placental sub totipotent stem cells, immune cells, adipose stem cells, and dental stem cells. It also provides genetic testing services related to non-invasive prenatal genetic testing during pregnancy, safe medication guide gene testing for children and adults, disease genetic testing, disease susceptibility gene testing, etc.; and in vitro diagnostic raw materials, such as monoclonal antibodies and polyclonal antibody products. In addition, the company is involved in the research, development, production, and sales of biological genes, proteins, antibodies, pharmaceutical intermediates, and experimental synthetic agents; and in vitro diagnostic reagents and medical devices. Vcanbio Cell & Gene Engineering Corp., Ltd was founded in 1992 and is based in Tianjin, the People's Republic of China.

Similar companies

600664.SS

Harbin Pharmaceutical Group Co., Ltd.

USD 0.52

4.12%

600633.SS

Zhejiang Daily Digital Culture Group Co.,Ltd.

USD 1.31

5.13%

600666.SS

Aurora Optoelectronics Co.,Ltd.

USD 0.31

6.52%

600618.SS

Shanghai Chlor-Alkali Chemical Co., Ltd.

USD 1.61

1.99%

600636.SS

China Reform Culture Holdings Co., Ltd.

USD 1.19

3.57%

StockViz Staff

January 16, 2025

Any question? Send us an email